Login to Your Account



Medicines Co. dual wins calm Angiomax angst

By Randy Osborne
Staff Writer

Friday, May 1, 2015

The Medicines Co. may have prospectively eased the pain of generic competition that looms for flagship product Angiomax (bivalirudin) by winning FDA approval of two drug-device combo therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription